Related references
Note: Only part of the references are listed.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Jharna Datta et al.
MOLECULAR CANCER THERAPEUTICS (2017)
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Leisl M. Packer et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
Alberto Ocana et al.
ONCOTARGET (2017)
Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer
Florian Malchers et al.
CLINICAL CANCER RESEARCH (2017)
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy
Antonino Musolino et al.
BREAST CANCER RESEARCH (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
Fabrice Andre et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
Stephane Terry et al.
ONCOTARGET (2015)
Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
Florian Malchers et al.
CANCER DISCOVERY (2014)
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
Sampurna Chatterjee et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Maria Teresa Herrera-Abreu et al.
CANCER DISCOVERY (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma
Eleni Mylona et al.
GYNECOLOGIC ONCOLOGY (2007)
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Lentivirus-delivered stable gene silencing by RNAi in primary cells
SA Stewart et al.
RNA (2003)
Share Paper
